- Home
- GLUE vs CHPT Comparison
GLUE vs CHPT Comparison
Compare GLUE & CHPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLUE
- CHPT
- Stock Information
- Founded
- GLUE 2019
- CHPT 2007
- Country
- GLUE United States
- CHPT United States
- Employees
- GLUE N/A
- CHPT N/A
- Industry
- GLUE Biotechnology: Pharmaceutical Preparations
- CHPT Industrial Specialties
- Sector
- GLUE Health Care
- CHPT Consumer Discretionary
- Exchange
- GLUE Nasdaq
- CHPT Nasdaq
- Market Cap
- GLUE 351.2M
- CHPT 340.1M
- IPO Year
- GLUE 2021
- CHPT N/A
- Fundamental
- Price
- GLUE $4.80
- CHPT $11.29
- Analyst Decision
- GLUE Buy
- CHPT Hold
- Analyst Count
- GLUE 2
- CHPT 10
- Target Price
- GLUE $13.50
- CHPT $29.13
- AVG Volume (30 Days)
- GLUE 369.2K
- CHPT 532.9K
- Earning Date
- GLUE 08-07-2025
- CHPT 09-03-2025
- Dividend Yield
- GLUE N/A
- CHPT N/A
- EPS Growth
- GLUE N/A
- CHPT N/A
- EPS
- GLUE 0.29
- CHPT N/A
- Revenue
- GLUE $177,986,000.00
- CHPT $407,681,000.00
- Revenue This Year
- GLUE $83.76
- CHPT $2.79
- Revenue Next Year
- GLUE N/A
- CHPT $24.20
- P/E Ratio
- GLUE $16.32
- CHPT N/A
- Revenue Growth
- GLUE 2990.57
- CHPT N/A
- 52 Week Low
- GLUE $3.50
- CHPT $8.55
- 52 Week High
- GLUE $12.40
- CHPT $39.20
- Technical
- Relative Strength Index (RSI)
- GLUE 51.69
- CHPT 47.09
- Support Level
- GLUE $4.54
- CHPT $11.41
- Resistance Level
- GLUE $4.93
- CHPT $11.85
- Average True Range (ATR)
- GLUE 0.21
- CHPT 0.59
- MACD
- GLUE 0.06
- CHPT 0.08
- Stochastic Oscillator
- GLUE 81.43
- CHPT 39.55
About GLUE Monte Rosa Therapeutics Inc.
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.
About CHPT ChargePoint Holdings Inc.
ChargePoint Holdings Inc designs, develops, and markets networked electric vehicle charging system infrastructure and cloud-based services that enable consumers to locate, reserve, and authenticate EV charging. The company's hardware product lineup includes solutions across home, commercial, and fast-charging applications. ChargePoint derives the majority of its revenue from the United States.